[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.167.149.128. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 794
Citations 0
Research Letter
September 2016

Use of Opioid Agonist Therapy for Medicare Patients in 2013

Author Affiliations
  • 1Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California
  • 2Department of Medicine, Stanford University School of Medicine, Stanford, California
JAMA Psychiatry. 2016;73(9):990-992. doi:10.1001/jamapsychiatry.2016.1390

Despite public policy efforts to prevent opioid overdose and addiction, opioid overdose rates reached record high numbers in 2014.1 The population that uses Medicare, the federal insurance program for Americans who have certain disabilities or are 65 years or older, has among the highest and most rapidly growing prevalence of opioid use disorder, with more than 6 of every 1000 patients (more than 300 000 of 55 million) diagnosed2 and with hospitalizations increasing 10% per year.3 Data on patients with commercial insurance plans (the other likely source for national population data) show just more than 1 of every 1000 patients diagnosed.2 Prevention initiatives are essential for reducing the number of new patients with opioid use disorder, but treatment will be required for those already addicted to opioids. Opioid agonist therapy (OAT), including buprenorphine-naloxone (Suboxone) and methadone, is the most effective pharmacotherapy for opioid addiction.4

First Page Preview View Large
First page PDF preview
First page PDF preview
×